Biodol Therapeutics, a French biotech company developing nextgeneration pain treatments announces its selection for funding by BPI France via the i-DEMO call for projects to finance its first-in-human clinical trials.

With the parallel support of the venture capital fund V-Bio Ventures, Biodol Therapeutics will lead a consortium also composed of 2 academic partners (Institute for Neurosciences of Montpellier and Laboratory for Therapeutic Innovation in Strasbourg), which will be eligible to receive a total of €7 million, either in equity and in non-dilutive, to develop its innovative program of small-molecule extracellular negative allosteric modulators (NAMs) of the FLT3 receptor.

The funding package will namely support the first-in-human clinical studies with the most advanced compound, BDT272, which has gathered an excellent and complete GLP safety/toxicology data package alongside with exceptional activity in a wide range of preclinical pain models.

The key role of the FLT3 receptor in pain mechanisms and the potential benefit of its specific extracellular inhibition have now been highlighted in several international scientific publications. FLT3
negative allosteric modulation is emerging as a promising drug development innovation in an indication with high medical needs.

Biodol Therapeutics is a French academic spin-off focused on innovative pain medication, backed by a portfolio of patents held in co-ownership with several French research institutes (Universities of Montpellier and Strasbourg, INSERM and CNRS).

Its program, approved by the 2 French competitiveness clusters Eurobiomed and Biovalley France, is perfectly aligned with the priorities of the France 2030 plan and the French government to develop innovative companies with high value products in growth markets to strengthen France’s competitiveness and industrial capabilities.

The primary objective of the company is now to bring the BDT272 clinical candidate to the clinic by the end of 2024.

Press Release here